Kallikrein-related peptidase 4 (KLK4) mRNA predicts short-term relapse in colorectal adenocarcinoma patients

Cancer Letters

Volumn 330, Issue 1, 2013, Pages 106-112

  Kontos, Christos K ^a   Chantzis, Dimitrios ^a   Papadopoulos, Iordanis N ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Colon cancer; Kallikreins; Molecular tumor biomarker; Prognostic marker; Real time PCR

Indexed keywords

KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 4; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL PREDICTION; TUMOR VOLUME;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HUMANS; KALLIKREINS; PROGNOSIS; RECURRENCE; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84872877336     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.036     Document Type: Article

References (65)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Duffy M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin. Chem. 2001, 47:624-630.
3. Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., Somerfield M.R., Hayes D.F., Bast R.C., ASCO Update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006, 24(2006):5313-5327.
4. Selby J.V., Friedman G.D., Quesenberry C.P., Weiss N.S. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N. Engl. J. Med. 1992, 326:653-657.
5. Benvenuti S., Sartore-Bianchi A., Di Nicolantonio F., Zanon C., Moroni M., Veronese S., Siena S., Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007, 67:2643-2648.
6. Jhawer M., Goel S., Wilson A.J., Montagna C., Ling Y.H., Byun D.S., Nasser S., Arango D., Shin J., Klampfer L., Augenlicht L.H., Perez-Soler R., Mariadason J.M. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res. 2008, 68:1953-1961.
7. Yousef G.M., Diamandis E.P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 2001, 22:184-204.
8. Borgono C.A., Michael I.P., Diamandis E.P. Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. 2004, 2:257-280.
9. Kontos C.K., Scorilas A. Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkers. Clin. Chem. Lab. Med.: CCLM/FESCC 2012, 50:1877-1891.
10. Avgeris M., Mavridis K., Scorilas A. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies. Biol. Chem. 2010, 391:505-511.
11. Talieri M., Li L., Zheng Y., Alexopoulou D.K., Soosaipillai A., Scorilas A., Xynopoulos D., Diamandis E.P. The use of kallikrein-related peptidases as adjuvant prognostic markers in colorectal cancer. Br. J. Cancer 2009, 100:1659-1665.
12. Yu X., Tang H.Y., Li X.R., He X.W., Xiang K.M. Over-expression of human kallikrein 11 is associated with poor prognosis in patients with low rectal carcinoma. Med. Oncol. 2010, 27:40-44.
13. Debela M., Magdolen V., Schechter N., Valachova M., Lottspeich F., Craik C.S., Choe Y., Bode W., Goettig P. Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J. Biol. Chem. 2006, 281:25678-25688.
14. Ohler A., Debela M., Wagner S., Magdolen V., Becker-Pauly C. Analyzing the protease web in skin: meprin metalloproteases are activated specifically by KLK4, 5 and 8 vice versa leading to processing of proKLK7 thereby triggering its activation. Biol. Chem. 2010, 391:455-460.
15. Takayama T.K., McMullen B.A., Nelson P.S., Matsumura M., Fujikawa K. Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001, 40:15341-15348.
16. Borgono C.A., Gavigan J.A., Alves J., Bowles B., Harris J.L., Sotiropoulou G., Diamandis E.P. Defining the extended substrate specificity of kallikrein 1-related peptidases. Biol. Chem. 2007, 388:1215-1225.
17. Matsumura M., Bhatt A.S., Andress D., Clegg N., Takayama T.K., Craik C.S., Nelson P.S. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 2005, 62:1-13.
18. Hekim C., Riipi T., Weisell J., Narvanen A., Koistinen R., Stenman U.H., Koistinen H. Identification of IGFBP-3 fragments generated by KLK2 and prevention of fragmentation by KLK2-inhibiting peptides. Biol. Chem. 2010, 391:475-479.
19. Takayama T.K., Fujikawa K., Davie E.W. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J. Biol. Chem. 1997, 272:21582-21588.
20. Stephenson S.A., Verity K., Ashworth L.K., Clements J.A. Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J. Biol. Chem. 1999, 274:23210-23214.
21. Nelson P.S., Gan L., Ferguson C., Moss P., Gelinas R., Hood L., Wang K. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc. Natl. Acad. Sci. USA 1999, 96:3114-3119.
22. Yousef G.M., Obiezu C.V., Luo L.Y., Black M.H., Diamandis E.P. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res. 1999, 59:4252-4256.
23. Kurlender L., Borgono C., Michael I.P., Obiezu C., Elliott M.B., Yousef G.M., Diamandis E.P. A survey of alternative transcripts of human tissue kallikrein genes. Biochim. Biophys. Acta 2005, 1755:1-14.
24. Obiezu C.V., Scorilas A., Katsaros D., Massobrio M., Yousef G.M., Fracchioli S., Rigault de la Longrais I.A., Arisio R., Diamandis E.P. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin. Cancer Res. 2001, 7:2380-2386.
25. Xi Z., Klokk T.I., Korkmaz K., Kurys P., Elbi C., Risberg B., Danielsen H., Loda M., Saatcioglu F. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res. 2004, 64:2365-2370.
26. Avgeris M., Stravodimos K., Scorilas A. Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: quantitative expression analysis and evaluation of its clinical significance. Prostate 2011, 71:1780-1789.
27. Papachristopoulou G., Avgeris M., Scorilas A. Expression analysis and study of KLK4 in benign and malignant breast tumours. Thromb. Haemost. 2009, 101:381-387.
28. Gratio V., Beaufort N., Seiz L., Maier J., Virca G.D., Debela M., Grebenchtchikov N., Magdolen V., Darmoul D. Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells. Am. J. Pathol. 2010, 176:1452-1461.
29. Dukes C.E. The classification of cancer of the rectum. J. Pathol. Bacteriol. 1932, 35:323.
30. Astler V.B., Coller F.A. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann. Surg. 1954, 139:846-852.
31. Nagtegaal I.D., Quirke P., Schmoll H.J. Has the new TNM classification for colorectal cancer improved care? Nature reviews. Clin. Oncol. 2012, 9:119-123.
32. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
33. Kheirelseid E.A., Chang K.H., Newell J., Kerin M.J., Miller N. Identification of endogenous control genes for normalisation of real-time quantitative PCR data in colorectal cancer. BMC Mol. Biol. 2010, 11:12.
34. Dydensborg A.B., Herring E., Auclair J., Tremblay E., Beaulieu J.F. Normalizing genes for quantitative RT-PCR in differentiating human intestinal epithelial cells and adenocarcinomas of the colon. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G1067-1074.
35. Camp R.L., Dolled-Filhart M., Rimm D.L. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 2004, 10:7252-7259.
36. Chung D.C. The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000, 119:854-865.
37. Mook O.R., Frederiks W.M., Van Noorden C.J. The role of gelatinases in colorectal cancer progression and metastasis. Biochim. Biophys. Acta 2004, 1705:69-89.
38. Liotta L.A., Kohn E.C. The microenvironment of the tumour-host interface. Nature 2001, 411:375-379.
39. Lopez-Otin C., Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 2007, 7:800-808.
40. Borgono C.A., Diamandis E.P. The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 2004, 4:876-890.
41. Paliouras M., Borgono C., Diamandis E.P. Human tissue kallikreins: the cancer biomarker family. Cancer Lett. 2007, 249:61-79.
42. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., Ladd C., Beheshti J., Bueno R., Gillette M., Loda M., Weber G., Mark E.J., Lander E.S., Wong W., Johnson B.E., Golub T.R., Sugarbaker D.J., Meyerson M. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA 2001, 98:13790-13795.
43. Planque C., Choi Y.H., Guyetant S., Heuze-Vourc'h N., Briollais L., Courty Y. Alternative splicing variant of kallikrein-related peptidase 8 as an independent predictor of unfavorable prognosis in lung cancer. Clin. Chem. 2010, 56:987-997.
44. Planque C., Kulasingam V., Smith C.R., Reckamp K., Goodglick L., Diamandis E.P. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol. Cell. Proteomics 2009, 8:2746-2758.
45. Yousef G.M., Borgono C.A., Popalis C., Yacoub G.M., Polymeris M.E., Soosaipillai A., Diamandis E.P. In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. Anticancer Res. 2004, 24:43-51.
46. Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M., Hruban R.H. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003, 63:8614-8622.
47. Konstantoudakis G., Florou D., Mavridis K., Papadopoulos I.N., Scorilas A. Kallikrein-related peptidase 13 (KLK13) gene expressional status contributes significantly in the prognosis of primary gastric carcinomas. Clin. Biochem. 2010, 43:1205-1211.
48. Scorilas A., Mavridis K. Kallikrein-related peptidases (KLKs) as novel potential biomarkers in gastric cancer: An open yet challenging road lies ahead. J. Surg. Oncol. 2012, 105:223-224.
49. Chung C.H., Parker J.S., Karaca G., Wu J., Funkhouser W.K., Moore D., Butterfoss D., Xiang D., Zanation A., Yin X., Shockley W.W., Weissler M.C., Dressler L.G., Shores C.G., Yarbrough W.G., Perou C.M. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004, 5:489-500.
50. Zhao H., Dong Y., Quan J., Smith R., Lam A., Weinstein S., Clements J., Johnson N.W., Gao J. Correlation of the expression of human kallikrein-related peptidases 4 and 7 with the prognosis in oral squamous cell carcinoma. Head Neck 2011, 33:566-572.
51. Roman-Gomez J., Jimenez-Velasco A., Agirre X., Castillejo J.A., Barrios M., Andreu E.J., Prosper F., Heiniger A., Torres A. The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. Leukemia 2004, 18:362-365.
52. Talieri M., Alexopoulou D.K., Scorilas A., Kypraios D., Arnogiannaki N., Devetzi M., Patsavela M., Xynopoulos D. Expression analysis and clinical evaluation of kallikrein-related peptidase 10 (KLK10) in colorectal cancer. Tumour Biol. 2011, 32:737-744.
53. Talieri M., Mathioudaki K., Prezas P., Alexopoulou D.K., Diamandis E.P., Xynopoulos D., Ardavanis A., Arnogiannaki N., Scorilas A. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb. Haemost. 2009, 101:741-747.
54. Loeb S., Catalona W.J. Prostate-specific antigen in clinical practice. Cancer Lett. 2007, 249:30-39.
55. Stephan C., Cammann H., Meyer H.A., Lein M., Jung K. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett. 2007, 249:18-29.
56. Xi Z., Kaern J., Davidson B., Klokk T.I., Risberg B., Trope C., Saatcioglu F. Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol. Oncol. 2004, 94:80-85.
57. Adams M., Calvert A.H., Carmichael J., Clark P.I., Coleman R.E., Earl H.M., Gallagher C.J., Ganesan T.S., Gore M.E., Graham J.D., Harper P.G., Jayson G.C., Kaye S.B., Ledermann J.A., Osborne R.J., Perren T.J., Poole C.J., Radford J.A., Rustin G.J., Slevin M.L., Smyth J.F., Thomas H., Wilkinson P.M. Chemotherapy for ovarian cancer-a consensus statement on standard practice. Br. J. Cancer 1998, 78:1404-1406.
58. Shaw J.L., Diamandis E.P. Distribution of 15 human kallikreins in tissues and biological fluids. Clin. Chem. 2007, 53:1423-1432.
59. Darmoul D., Gratio V., Devaud H., Lehy T., Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am. J. Pathol. 2003, 162:1503-1513.
60. Heider I., Schulze B., Oswald E., Henklein P., Scheele J., Kaufmann R. PAR1-type thrombin receptor stimulates migration and matrix adhesion of human colon carcinoma cells by a PKCepsilon-dependent mechanism. Oncol. Res. 2004, 14:475-482.
61. Goerge T., Barg A., Schnaeker E.M., Poppelmann B., Shpacovitch V., Rattenholl A., Maaser C., Luger T.A., Steinhoff M., Schneider S.W. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation. Cancer Res. 2006, 66:7766-7774.
62. Obiezu C.V., Shan S.J., Soosaipillai A., Luo L.Y., Grass L., Sotiropoulou G., Petraki C.D., Papanastasiou P.A., Levesque M.A., Diamandis E.P. Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clin. Chem. 2005, 51:1432-1442.
63. Seiz L., Kotzsch M., Grebenchtchikov N.I., Geurts-Moespot A.J., Fuessel S., Goettig P., Gkazepis A., Wirth M.P., Schmitt M., Lossnitzer A., Sweep F.C., Magdolen V. Polyclonal antibodies against kallikrein-related peptidase 4 (KLK4): immunohistochemical assessment of KLK4 expression in healthy tissues and prostate cancer. Biol. Chem. 2010, 391:391-401.
64. Feng B., Xu W.B., Zheng M.H., Ma J.J., Cai Q., Zhang Y., Ji J., Lu A.G., Qu Y., Li J.W., Wang M.L., Hu W.G., Liu B.Y., Zhu Z.G. Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. J. Gastroenterol. Hepatol. 2006, 21:1596-1603.
65. Ogawa K., Utsunomiya T., Mimori K., Tanaka F., Inoue H., Nagahara H., Murayama S., Mori M. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin. Cancer Res. 2005, 11:2889-2893.